References
- 1. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol. 2003;95:2106-2112.
- 2. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of withinsubject responses to fluticasone and montelukast in childhood asthma. J Allergy ClinImmunol. 2005;115:233-242.
- 3. Fischer A, Stegemann J, Scheuch G, Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res. 2009;14(Suppl. IV):71-77.
- 4. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102:1681-93.
- 5. Kotses H, Stout C, McConnaughy K, Winder JA, Creer TL. Evaluation of individualized asthma self-management programs. J Asthma. 1996;33(2):113-8.
- 6. Fingleton J, Beasley R. Individualized treatment for asthma. Advances in Asthma Management. 2012;156-166.
- 7. Tantisira KG et al. Genomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma. N Engl J Med. 2011;365:1173-1183.
- 8. Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev Respir Med. 2012;6(2):223-36.doi:10.1586/ers.12.9.
- 9. Poon AH, Hamid Q. Asthma Endotypes: The Right Direction Towards Personalized Medicine for Asthma. Expert Rev Clin Immunol. 2012;8(7):595-596.
- 10. Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. J Asthma. 2014;51(7):669-76.
- 11. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299-310.
- 12. Darveaux J, Busse WW. Biologics in Asthma - The Next Step Toward Personalized Treatment. The Journal of Allergy and Clinical Immunology: In Practice. 2015;3(2):152-160.
- 13. Sárkány Z, Horváth A, Balásházy I, Hofmann W, Brînzaniuc K, Sabău M. Evaluation of inhaled drug deposition during an asthma attack using a stochastic lung model. Acta Medica Transilvanica. 2013;2(1):238-240.
- 14. Sárkány Z. Maximizing the amount of deposited particles during a severe asthma attack using the stochastic lung model. Acta Medica Marisiensis 2015;61(3):157-160.doi:10.1515/amma-2015-0043.
- 15. Stocks J, Quanjer PhH. Reference values for residual volume, functional residual capacity and total lung capacity. Eur Respir J. 1995;8:492-506.
- 16. Martonen TB, Fleming J, Schroeter J, Conway J, Hwang D. In silico modelling of asthma. Advanced. Drug Delivery Reviews. 2003;55:829-849.
- 17. Chalupa DC, Morrow PE, Oberdorster G, Utell MJ, Frampton MW. Ultrafine particle deposition in subjects with asthma. Environmental Health Perspectives. 2004;112:879-882.
- 18. Longest PW, Vinchurkar S, Martonen T. Transport and deposition of respiratory aerosols in models of childhood asthma. Journal of Aerosol Science. 2006;37:1234-1257.
- 19. Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. Chest. 2006 Sep;130(3):827-33.